Beyond a Surface Marker: The Multifaceted Role of CD38 in Metabolic Disruption and Tumor Progression
CELL BIOCHEMISTRY AND BIOPHYSICS, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Basım Tarihi: 2026
- Doi Numarası: 10.1007/s12013-026-02133-w
- Dergi Adı: CELL BIOCHEMISTRY AND BIOPHYSICS
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE, MEDLINE, Natural Science Collection (ProQuest), Biological Science Database (ProQuest), Biomedical Reference Collection: Corporate Edition (EBSCO), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Çanakkale Onsekiz Mart Üniversitesi Adresli: Evet
Özet
CD38 is a type II transmembrane glycoprotein and serves as the primary ectoenzyme responsible for regulating cellular nicotinamide adenine dinucleotide (NAD+) levels in mammalian tissues. Initially identified as a lymphocyte activation marker, recent research has revealed its significant role in immunosuppression within oncological processes, NAD+ depletion associated with aging, and exosomal signaling. This review provides a comprehensive analysis of the enzymatic functions of CD38, its pathophysiological impacts on both hematological and solid tumors, and the mechanisms of resistance that emerge against anti-CD38 therapies. Furthermore, the potential of CD38 as an exosomal biomarker in liquid biopsy procedures and its function as a "metabolic resetter" for promoting healthy aging are explored.